CyFlow CD135 PE
| 品番 | BJ941654 | ||
|---|---|---|---|
| 抗体名 | Anti-Hu CD135 PE,BV10A4 | ||
| 包装単位 | 100 tests | ||
| 濃度 | - | ||
| 容量 | 2 ml | ||
| 関連製品 (アイソタイプコントロール) |
Mouse IgG1 PE (BV655324) |
||
| 反応性|交差吸着 | Human | レーザー | Blue, Green, Yellow |
| 抗原 | CD135, Flt3, Flk2, STK1 | 最大蛍光波長 | 576 nm |
| クローン | BV10A4 | 最大励起波長 | 496 nm, 565 nm |
| ホスト | Mouse | 標識/Format | PE |
| アイソタイプ | IgG1 | 研究分野 | Immunophenotyping | Phosphorylation |
| クローナリティ | monoclonal | 用途 | Flow cytometry |
Anti-Hu CD135 PE,BV10A4
特異性
The mouse monoclonal antibody BV10A4 (BV10) reacts with CD135 antigen, a 130-160 kDa type III receptor tyrosine kinase that is involved in early steps of hematopoiesis
抗原情報
CD135 (FLT3, FLK2, STK-1) is a receptor tyrosine kinase that plays important roles in hematopoiesis. After binding of FLT3 ligand (FL), CD135 homodimerizes and stimulates proliferation, differentiation and protects the cell from apoptosis. The loss of CD90 and gain of CD135 expression marks the loss of self-renewal in hematopoietic stem cell population. Detectable CD135 expression appears first at low levels on the surface of primitive multilineage progenitor cells and disappears during defined stages of B-cell development but is upregulated and maintained during maturation of monocytes. CD135 is also expressed on thymocytes, dendritic cell progenitors and on mature dendritic cells, as well as on various malignant hematopoietic cells.
利用方法
The reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 20 µl reagent / 100 µl of whole blood or 10^6 cells in a suspension. The content of a vial (2 ml) is sufficient for 100 tests.
保存方法
Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
安定性情報
Do not use after expiration date stamped on vial label.
レファレンス
• Christensen JL, Weissman IL: Flk‑2 is a marker in hematopoietic stem cell differentiation: a simple method to isolate long‑term stem cells: a simple method to isolate long‑term stem cells. Proc·Natl·Acad·Sci·USA. 2001·Dec·4; 98(25):14541‑6. <·PMID:·11724967·>
• Haylock DN, Horsfall MJ, Dowse TL, Ramshaw HS, Niutta S, Protopsaltis S, Peng L, Burrell C, Rappold I, Buhring HJ, Simmons PJ: Increased recruitment of hematopoietic progenitor cells underlies the ex vivo expansion potential of FLT3 ligand. Blood. 1997·Sep·15; 90(6):2260‑72. <·PMID:·9310477·>
• Kuchenbauer F, Kern W, Schoch C, Kohlmann A, Hiddemann W, Haferlach T, Schnittger S: Detailed analysis of FLT3 expression levels in acute myeloid leukemia. Haematologica. 2005·Dec; 90(12):1617‑25. <·PMID:·16330434·>
• Rappold I, Ziegler BL, Köhler I, Marchetto S, Rosnet O, Birnbaum D, Simmons PJ, Zannettino AC, Hill B, Neu S, Knapp W, Alitalo R, Alitalo K, Ullrich A, Kanz L, Bühring HJ: Functional and phenotypic characterization of cord blood and bone marrow subsets expressing FLT3 (CD135) receptor tyrosine kinase. Blood. 1997·Jul·1; 90(1):111‑25. <·PMID:·9207445·>
• Whartenby KA, Calabresi PA, McCadden E, Nguyen B, Kardian D, Wang T, Mosse C, Pardoll DM, Small D: Inhibition of FLT3 signaling targets DCs to ameliorate autoimmune disease. Proc·Natl·Acad·Sci·USA. 2005·Nov·15; 102(46):16741‑6. <·PMID:·16272221·>
• Kishimoto T, Goyert S, Kikutani H, Mason D, Miyasaka M, Moretta L, Ohno T, Okumura K, Shaw S, Springer TA, Sugamura K, Sugawara H, von dem Borne AEGK, Zola H (Eds): Leucocyte Typing VI. Garland·Publishing·Inc,·New·York. 1997; 1‑1342. <·NLM·ID:·9712219·>
Available Safety Data Sheets
CyFlow™ monoclonal antibodies SDS CA EN